SEROTYPES AND ANTIMICROBIAL SUSCEPTIBILITY OF NASOPHARYNGEAL PNEUMOCOCCI ISOLATED FROM CHILDREN IN 2010–2016: A RETROSPECTIVE COHORT STUDY

Background. Pneumococci (Streptococcus pneumoniae) represent major pathogens that cause acute infections in children. Objective. Our aim was to analyze dynamics of the distribution of nasopharyngeal pneumococcal serotypes and their antimicrobial susceptibility in children. Methods. A retrospective cohort study was conducted. We examined nasopharyngeal pneumococci isolated from children getting care at the National Medical Research Center of Children’s Health (Moscow) in 2010–2016. Serotyping was performed using specific antisera and/or by molecular typing employing PCR. Susceptibility to oxacillin (OXA), erythromycin (ERY), clindamycin (CLI), trimethoprim/sulfamethoxazol, chloramphenicol and tetracycline was tested by the disk diffusion method. In 2013–2016, penicillin (PEN), amoxicillin (AMX), ERY and CLI minimal inhibitory concentrations (MIC) were measured. Results. A total of 1,111 pneumococcal isolates were examined; the sample was obtained from children with a median age of 4 years (P25–P75, 2.4–6.5 years). We identified 48 pneumococcal serotypes; six leading serotypes were serotypes 3, 6А, 6В, 14, 19F and 23F aggregating a proportion of 63.2% in the overall distribution. From 2010 to 2016, the distribution of serotypes has not changed. Wherein, 13-valent pneumococcal conjugate vaccine covered 74% of serotypes in children under 5 years. The five leading serotypes (6А, 6В, 14, 19F, 23F and serotype 19A) had the highest resistance rate. Within 2010–2016, the proportion of OXA- and ERY-resistant pneumococci grew from 21.3% to 35.9% and from 24.5% to 36.9%, respectively. The majority (81.3%) of ERY-resistant isolates possessed an MLSB-phenotype, i. e. were resistant to macrolides, lincosamides, and streptogramin B. In 2013–2016, the rate of PEN- and AMX-resistant pneumococci was 34.6% and 3.5%, respectively. Conclusion. Within the seven year study period, no major shifts in the nasopharyngeal pneumococcal serotype distribution were observed. The pneumococci remained highly susceptible to AMX, but activity of macrolides was significantly reduced. Considering the leading mechanism of macrolide resistance, the use of any macrolides or lincosamides for empiric treatment of pneumococcal infections in children is questionable.

1. Croucher NJ, Harris SR, Fraser C, et al. Rapid pneumococcal evolution in response to clinical interventions. Science. 2011; 331(6016):430–434. doi: 10.1126/science.1198545.

2. Henriques-Normark B, Blomberg C, Dagerhamn J, et al. The rise and fall of bacterial clones: streptococcus pneumoniae. Nat Rev Microbiol. 2008;6(11):827–837. doi: 10.1038/nrmicro2011.

3. Richter SS, Musher DM. The ongoing genetic adaptation of Streptococcus pneumoniae. J Clin Microbiol. 2017;55(3):681–685. doi: 10.1128/JCM.02283-16.

4. Goossens H. Antibiotic consumption and link to resistance. Clin Microbiol Infect. 2009;15 Suppl 3:12–15. doi: 10.1111/j.1469-0691.2009.02725.x.

5. Azzari C, Martinon-Torres F, Schmitt HJ, Dagan R. Evolving role of 13-valent pneumococcal conjugate vaccine in clinical practice. Pediatr Infect Dis J. 2014;33(8):858–864. doi: 10.1097/ INF.0000000000000328.

6. Richter SS, Diekema DJ, Heilmann KP, et al. Changes in pneumococcal serotypes and antimicrobial resistance after introduction of the 13-valent conjugate vaccine in the United States. Antimicrob Agents Chemother. 2014;58(11):6484–6489. doi: 10.1128/AAC.03344-14.

7. van der Linden M, Falkenhorst G, Perniciaro S, et al. Effectiveness of Pneumococcal Conjugate Vaccines (PCV7 and PCV13) against invasive pneumococcal disease among children under two years of age in Germany. PLoS One. 2016;11(8):e0161257. doi: 10.1371/ journal.pone.0161257.

8. Рудакова А.В., Баранов А.А., Лобзин Ю.В., и др. Фармакоэкономические аспекты вакцинации детей 13-валентной пневмококковой конъюгированной вакциной в Российской Федерации // Вопросы современной педиатрии. — 2014. — Т. 13. — № 1 — С. 51–59. [Rudakova AV, Baranov AA, Lobzin YuV, et al. Pharmacoeconomic assessment of 13-valent pneumococ-cal conjugate vaccine in immunization of children in Russian Federation. Current pediatrics. 2014;13(1):51–59. (In Russ).] doi: 10.15690/vsp.v13i1.911.

9. Приказ Министерства здравоохранения РФ от 21 марта 2014 г. № 125н «Об утверждении национального календаря профилактических прививок и календаря профилактических прививок по эпидемическим показаниям». [Order of the Ministry of Public Health RF dated March 21, 2014 № 125n «Ob utverzhdenii natsional’nogo kalendarya profilakticheskikh privivok i kalendarya profilakticheskikh privivok po epidemicheskim pokazaniyam». (In Russ).]

10. Баранов А.А., Намазова-Баранова Л.С., Маянский Н.А., и др. Роль Streptococcus pneumoniae в структуре бактериальных инфекций у детей, госпитализированных в стационары г. Москвы в 2011–2012 гг. // Педиатрическая фармакология. — 2013. — Т. 10. — № 5 — С. 6–12. [Baranov AA, Namazova-Baranova LS, Mayanskii NA, et al. Role of Streptococcus pneumoniae in the structure of bacterial infections in the children hospitalized to inpatient hospitals in Moscow in 2011– 2012. Pediatric pharmacology. 2013;10(5):6–12. (In Russ).] doi: 10.15690/pf.v10i5.816.

11. Белошицкий Г.В., Королева И.С., Королева М.А. Серотиповой пейзаж пневмококков, выделенных при пневмококковом менингите, в Российской Федерации // Эпидемиология и вакцинопрофилактика. — 2015. — Т. 14. — № 2 — С. 19–25. [Beloshitsky GV, Koroleva IS, Koroleva MA. Landscape of serotypes pneumococcus isolate with pneumococcal meningitis in the Russian Federation. Epidemiol Vakcinoprofil. 2015;14(2):19–25. (In Russ).]